| Zoledronic acid in breast cancer: latest findings and interpretations. | |
| | |
MedLine Citation:
|
PMID: 22084643 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies. Moreover, clinical data from the ABCSG-12 and ZO-FAST trials demonstrate significantly improved disease-free survival with zoledronic acid in the adjuvant breast cancer setting. In contrast to these two trials, recent interim results from the AZURE trial do not show a benefit from adding zoledronic acid to adjuvant therapy in the overall patient population. However, subset analyses of AZURE data show that zoledronic acid significantly improved overall survival in women who were more than 5 years postmenopausal or older than 60 years at baseline. Similarly, subset analyses of the ABCSG-12 trial data demonstrate greater benefits from zoledronic acid treatment in patients who theoretically would have achieved more complete ovarian suppression. These observations, together with the AZURE postmenopausal data, suggest that the endocrine environment may affect the potential anticancer activity of zoledronic acid. Indeed, current data support the possibility that zoledronic acid might be most effective for improving disease-free survival in the adjuvant breast cancer setting in women who are postmenopausal or have endocrine therapy-induced menopause. |
| | |
Authors:
|
Michael Gnant |
Related Documents
:
|
22516933 - Dihydrochalcones and benzoic acid derivatives from piper dennisii. 22445843 - Fragrance material review on 1,1-dimethyl-2-phenylethyl acetate. 11665813 - Chum salmon trypsin-catalyzed preferential formation of peptides containing d-amino acid. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Therapeutic advances in medical oncology Volume: 3 ISSN: 1758-8359 ISO Abbreviation: Ther Adv Med Oncol Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101510808 Medline TA: Ther Adv Med Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 293-301 Citation Subset: - |
Affiliation:
|
Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The potential for crizotinib in non-small cell lung cancer: a perspective review.
Next Document: Malignant melanoma in the elderly: different regional disease and poorer prognosis.